Posted by Michael Wonder on 02 Aug 2016
Ospemifene in vulvovaginal atrophy: additional clinical benefits not seen says IQWiG
1 August 2016 - Incorrect study population, studies were too short.
Ospemifene (Senshio) is approved to treat women who have moderate to severe post-menopausal vulvovaginal atrophy. The IQWiG has investigated in an early benefit assessment whether the medicine has advantages and disadvantages compared to the appropriate comparator therapy.
Since none of the three studies in the submission lodged by the manufacturer is suitable, the IQWiG has concluded that an additional clinical benefit of ospemifene versus the appropriate comparator therapy (best supportive care) has not been established.
